
Laboratory Management
Please note:
Adobe PDF Reader is required to view clinical guideline documents.
There may be instances in which your health plan policies take precedence over the EviCore by Evernorth clinical guidelines. If you have any questions, please reach out to your health plan.
Follow the below steps to access the clinical guidelines.
- Enter your Health Plan name into the search field and click on the magnifying glass.
- To access the guideline specific to your request, locate the guideline that the decision was based on from within your letter.
- Identify the guideline title and then search for that guideline title by scrolling down on the page or entering the guideline title into the guideline title search field.
- Open the guideline document.
Example:
The statement in your letter reads:
We based this decision on the guideline as listed below:
-MTHFR Variant Analysis for Hyperhomocysteinemia (MOL.TX.205).
Enter your Health Plan name into the search field and click on the magnifying glass.
Enter the guideline title into the search field for the guideline name.
Once the search results appear, click on the guideline to open it.
If you require a copy of the guidelines that were used to make a determination on a specific request of treatment or services, please email the case number and request to: reqcriteria@EviCore.com.
To request any additional assistance in accessing the guidelines, provide feedback or clinical evidence related to the evidence-based guidelines, please click here.
EviCore coverage policies include background and supporting information and citations for sources used to develop the policy. Some clinical policies may have a supplemental literature summary available which will provide additional commentary regarding clinical benefits and harms to the patient population being served. Additional literature summaries may be accessed by selecting ‘Supplemental Information’ and then entering “EviCore by Evernorth” in the search by health plan function.
Code Lists
Guidelines
-
MOL.AD.107.A: Unique Test Identifiers for Non-Specific Procedure Codes
-
MOL.AD.304.A: Medical Necessity Review Information Requirements
-
MOL.AD.314.A: Date of Service and Authorization Period Effective Date
-
MOL.AD.364.A: Special Circumstances Influencing Coverage Determinations
-
MOL.AD.412.A: Laboratory Billing and Reimbursement
-
MOL.CU.109.A: Genetic Testing for Cancer Susceptibility and Hereditary Cancer Syndromes
-
MOL.CU.110.A: Genetic Testing for Carrier Status
-
MOL.CU.111.A: Genetic Testing for Non-Medical Purposes
-
MOL.CU.112.A: Genetic Testing for Prenatal Screening and Diagnostic Testing
-
MOL.CU.113.A: Genetic Testing for the Screening, Diagnosis, and Monitoring of Cancer
-
MOL.CU.114.A: Genetic Testing to Diagnose Non-Cancer Conditions
-
MOL.CU.115.A: Genetic Testing to Predict Disease Risk
-
MOL.CU.116.A: Genetic Testing by Multigene Panels
-
MOL.CU.117.A: Experimental, Investigational, or Unproven Laboratory Testing
-
MOL.CU.118.A: Pharmacogenomic Testing for Drug Toxicity and Response
-
MOL.CU.119.A: Preimplantation Genetic Screening and Diagnosis
-
MOL.CU.246.A: Hereditary (Germline) Testing After Tumor (Somatic) Testing
-
MOL.CU.256.A: Confirmatory Genetic Testing
-
MOL.CU.291.A: Genetic Testing for Known Familial Mutations
-
MOL.CU.292.A: Genetic Testing for Variants of Uncertain Clinical Significance
-
MOL.CU.333.B: Medically Necessary Laboratory Testing
-
MOL.TS.120.A: 4Kscore for Prostate Cancer Risk Assessment
-
MOL.TS.122.A: Afirma Thyroid Cancer Classifier Tests
-
MOL.TS.123.A: AlloMap Gene Expression Profiling For Heart Transplant Rejection
-
MOL.TS.124.A: Alpha-1 Antitrypsin Deficiency Testing
-
MOL.TS.125.A: Amyotrophic Lateral Sclerosis (ALS) Genetic Testing
-
MOL.TS.126.A: Angelman Syndrome Genetic Testing
-
MOL.TS.128.A: APOE Variant Analysis for Alzheimer Disease Testing
-
MOL.TS.129.A: Ashkenazi Jewish Carrier Screening
-
MOL.TS.130.A: Ataxia-Telangiectasia Genetic Testing
-
MOL.TS.144.A: CADASIL Genetic Testing
-
MOL.TS.148.A Charcot-Marie-Tooth Neuropathy Genetic Testing
-
MOL.TS.150.A: Chromosomal Microarray Testing For Developmental Disorders (Prenatal and Postnatal)
-
MOL.TS.151.A: Chromosome Analysis for Blood and Bone Marrow Cancers
-
MOL.TS.152.A: Cologuard Screening for Colorectal Cancer
-
MOL.TS.153.A: ConfirmMDx for Prostate Cancer Risk Assessment
-
MOL.TS.158.A: Cystic Fibrosis Genetic Testing
-
MOL.TS.159.A: Dentatorubral-Pallidoluysian Atrophy Genetic Testing
-
MOL.TS.161.A: Duchenne and Becker Muscular Dystrophy Testing
-
MOL.TS.162.A Early Onset Familial Alzheimer Disease Genetic Testing
-
MOL.TS.164.A: SEPT9 Methylation Analysis for Colorectal Cancer
-
MOL.TS.165.A: Carrier Screening Panels, Including Targeted, Pan-Ethnic, Universal, and Expanded
-
MOL.TS.168.A: Familial Adenomatous Polyposis Genetic Testing
-
MOL.TS.169.A: Familial Hypercholesterolemia Genetic Testing
-
MOL.TS.170.A: Familial Malignant Melanoma Genetic Testing
-
MOL.TS.172.A: FMR1-Related Disorders (Fragile X) Genetic Testing
-
MOL.TS.182.A: Hereditary Cancer Syndrome Multigene Panels
-
MOL.TS.183.A: HFE Hemochromatosis Genetic Testing
-
MOL.TS.188.A: Huntington Disease Genetic Testing
-
MOL.TS.193.A: Li-Fraumeni Syndrome Genetic Testing
-
MOL.TS.194.A: Liquid Biopsy Testing
-
MOL.TS.197.A: Lynch Syndrome Genetic Testing
-
MOL.TS.199.A: Lynch Syndrome Tumor Screening - Second-Tier
-
MOL.TS.200.A: Mammaprint 70-Gene Breast Cancer Recurrence Assay
-
MOL.TS.202.A: Marfan Syndrome Genetic Testing
-
MOL.TS.206.A: MUTYH Associated Polyposis Genetic Testing
-
MOL.TS.209.A: Non-Invasive Prenatal Screening
-
MOL.TS.211.A: Oncotype DX for Breast Cancer Prognosis
-
MOL.TS.213.A: Oncotype DX for Colorectal Cancer Recurrence Risk
-
MOL.TS.215.A: PCA3 Testing for Prostate Cancer
-
MOL.TS.216.A: Peutz-Jeghers Syndrome Genetic Testing
-
MOL.TS.217.A: Prader-Willi Syndrome Genetic Testing
-
MOL.TS.220.A: Prenatal Maternal Serum Screening
-
MOL.TS.222.A: Prosigna Breast Cancer Prognostic Gene Signature Assay
-
MOL.TS.223.A: PTEN Hamartoma Tumor Syndromes Genetic Testing
-
MOL.TS.224.A: Rett Syndrome Genetic Testing
-
MOL.TS.225.A: Spinal Muscular Atrophy Genetic Testing
-
MOL.TS.227.A: Thoracic Aortic Aneurysms and Dissections (TAAD) Panel Genetic Testing
-
MOL.TS.228.A: Tissue of Origin Testing for Cancer of Unknown Primary
-
MOL.TS.230.A: Somatic Mutation Testing
-
MOL.TS.232.A: VeriStrat Testing for NSCLC TKI Response
-
MOL.TS.233.A: Von Hippel-Lindau Disease Genetic Testing
-
MOL.TS.234.A: EndoPredict for Breast Cancer Prognosis
-
MOL.TS.235.A: Exome Sequencing
-
MOL.TS.236.A: Cxbladder
-
MOL.TS.238.A: BRCA Analysis
-
MOL.TS.240.A: BCR-ABL Negative Myeloproliferative Neoplasm Genetic Testing
-
MOL.TS.248.A: Breast Cancer Index for Breast Cancer Prognosis
-
MOL.TS.250.A: NETest
-
MOL.TS.251.A: PALB2 Genetic Testing for Cancer Risk
-
MOL.TS.254.A DecisionDX Uveal Melanoma
-
MOL.TS.255.A Oncotype DX Breast DCIS
-
MOL.TS.257.A Epilepsy Genetic Testing
-
MOL.TS.258.A Maturity-Onset Diabetes of the Young Genetic Testing
-
MOL.TS.259.A ThyGeNEXT and ThyraMIR miRNA Gene Expression Classifier
-
MOL.TS.260.A OVA1
-
MOL.TS.264.A SelectMDx
-
MOL.TS.266.A Mitochondrial Disorders Genetic Testing
-
MOL.TS.267.A Ehlers-Danlos Syndrome Genetic Testing
-
MOL.TS.268.A: Hereditary Connective Tissue Disorder Genetic Testing
-
MOL.TS.269.A Autism, Intellectual Disability, and Developmental Delay Genetic Testing
-
MOL.TS.270.A Thyroseq
-
MOL.TS.271.A PancraGEN
-
MOL.TS.273.A: Nonsyndromic Hearing Loss and Deafness Genetic Testing
-
MOL.TS.276.A Polymerase Gamma (POLG) Related Disorders Genetic Testing
-
MOL.TS.282.A: DermTech Pigmented Lesion Assay
-
MOL.TS.285.A: Multiple Endocrine Neoplasia Type 1 Genetic Testing
-
MOL.TS.286.A: Multiple Endocrine Neoplasia Type 2 Genetic Testing
-
MOL.TS.287.A: Hereditary Pancreatitis Genetic Testing
-
MOL.TS.288.A Limb-Girdle Muscular Dystrophy Genetic Testing
-
MOL.TS.290.A: Facioscapulohumeral Muscular Dystrophy Genetic Testing
-
MOL.TS.294.A Decipher Prostate Cancer Classifier
-
MOL.TS.295.A: Genomic Prostate Score
-
MOL.TS.297.A: Prolaris
-
MOL.TS.301.A: Neurofibromatosis Type 1 Genetic Testing
-
MOL.TS.302.A: Legius Syndrome Genetic Testing
-
MOL.TS.306.A: Genome Sequencing
-
MOL.TS.307.A: AlloSure for Kidney Transplant Rejection
-
MOL.TS.308.A: Hemoglobinopathies Genetic Testing
-
MOL.TS.309.A: Friedreich Ataxia Genetic Testing
-
MOL.TS.310.A: Hereditary Ataxia Multigene Panel Genetic Testing
-
MOL.TS.311.A: Spinocerebellar Ataxia Genetic Testing
-
MOL.TS.312.A: Myotonic Dystrophy Type 1 Genetic Testing
-
MOL.TS.324.A: CHARGE Syndrome and CHD7 Disorder Genetic Testing
-
MOL.TS.344.A: Chromosomal Microarray for Solid Tumors
-
MOL.TS.356.A: Microsatellite Instability and Immunohistochemistry Testing in Cancer
-
MOL.TS.359.A: Inflammatory Bowel Disease Biomarker Testing
-
MOL.TS.360.A: Inherited Bone Marrow Failure Syndrome (IBMFS) Testing
-
MOL.TS.361.A: Human Platelet and Red Blood Cell Antigen Genotyping
-
MOL.TS.370.A: Inherited Thrombophilia Genetic Testing
-
MOL.TS.371.A: Noonan Spectrum Disorder Genetic Testing
-
MOL.TS.396.A: Multi-Cancer Early Detection Screening
-
MOL.TS.401.A: Liver Fibrosis Assessment Biomarkers
-
MOL.TS.410.A: Cardiomyopathy and Arrhythmia Genetic Testing
-
MOL.TS.413.A: ColoSense for Colorectal Cancer
-
MOL.TS.419.A: Primary Ciliary Dyskinesia Genetic Testing
Code Lists
Code Lists
Guidelines
-
MOL.AD.107.A: Unique Test Identifiers for Non- Specific Procedure CodesEffective 02/01/2025 - 06/30/2025
-
MOL.AD.304.A: Medical Necessity Review Information RequirementsEffective 02/01/2025 - 06/30/2025
-
MOL.AD.314.A: Date of Service and Authorization Period Effective DateEffective 02/01/2025 - 06/30/2025
-
MOL.AD.364.A: Special Circumstances Influencing Coverage DeterminationsEffective 02/01/2025 - 06/30/2025
-
MOL.AD.412.A: Laboratory Billing and ReimbursementEffective 02/01/2025 - 06/30/2025
-
MOL.CU.109.A: Genetic Testing for Cancer Susceptibility and Hereditary Cancer SyndromesEffective 02/01/2025 - 06/30/2025
-
MOL.CU.110.A: Genetic Testing for Carrier StatusEffective 02/01/2025 - 06/30/2025
-
MOL.CU.111.A: Genetic Testing for Non-Medical PurposesEffective 02/01/2025 - 06/30/2025
-
MOL.CU.112.A: Genetic Testing for Prenatal Screening and Diagnostic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.CU.113.A: Genetic Testing for the Screening, Diagnosis, and Monitoring of CancerEffective 02/01/2025 - 06/30/2025
-
MOL.CU.114.A: Genetic Testing to Diagnose Non- Cancer ConditionsEffective 02/01/2025 - 06/30/2025
-
MOL.CU.115.A: Genetic Testing to Predict Disease RiskEffective 02/01/2025 - 06/30/2025
-
MOL.CU.116.A: Genetic Testing by Multigene PanelsEffective 02/01/2025 - 06/30/2025
-
MOL.CU.117.A Experimental, Investigational, or Unproven Laboratory TestingEffective 02/01/2025 - 06/30/2025
-
MOL.CU.118.A: Pharmacogenomic Testing for Drug Toxicity and ResponseEffective 02/01/2025 - 06/30/2025
-
MOL.CU.119.A: Preimplantation Genetic Screening and DiagnosisEffective 02/01/2025 - 06/30/2025
-
MOL.CU.246.A: Hereditary (Germline) Testing After Tumor (Somatic) TestingEffective 02/01/2025 - 06/30/2025
-
MOL.CU.256.A: Confirmatory Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.CU.291.A: Genetic Testing for Known Familial MutationsEffective 02/01/2025 - 06/30/2025
-
MOL.CU.292.A: Genetic Testing for Variants of Uncertain Clinical SignificanceEffective 02/01/2025 - 06/30/2025
-
MOL.CU.333.B: Medically Necessary Laboratory TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.120.A: 4Kscore for Prostate Cancer Risk AssessmentEffective 02/01/2025 - 06/30/2025
-
MOL.TS.122.A: Afirma Thyroid Cancer Classifier TestsEffective 02/01/2025 - 06/30/2025
-
MOL.TS.123.A: AlloMap Gene Expression Profiling For Heart Transplant RejectionEffective 02/01/2025 - 06/30/2025
-
MOL.TS.124.A: Alpha-1 Antitrypsin Deficiency TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.125.A: Amyotrophic Lateral Sclerosis (ALS) Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.126.A: Angelman Syndrome Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.128.A: APOE Variant Analysis for Alzheimer Disease TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.129.A: Ashkenazi Jewish Carrier ScreeningEffective 02/01/2025 - 06/30/2025
-
MOL.TS.130.A: Ataxia-Telangiectasia Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.144.A: CADASIL Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.148.A: Charcot-Marie-Tooth Neuropathy Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.150.A: Chromosomal Microarray Testing For Developmental Disorders (Prenatal and Postnatal)Effective 02/01/2025 - 06/30/2025
-
MOL.TS.151.A: Chromosome Analysis for Blood and Bone Marrow CancersEffective 02/01/2025 - 06/30/2025
-
MOL.TS.152.A: Cologuard Screening for Colorectal CancerEffective 02/01/2025 - 06/30/2025
-
MOL.TS.153.A: ConfirmMDx for Prostate Cancer Risk AssessmentEffective 02/01/2025 - 06/30/2025
-
MOL.TS.158.A: Cystic Fibrosis Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.159.A: Dentatorubral-Pallidoluysian Atrophy Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.161.A: Duchenne and Becker Muscular Dystrophy TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.162.A: Early Onset Familial Alzheimer Disease Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.164.A: SEPT9 Methylation Analysis for Colorectal CancerEffective 02/01/2025 - 06/30/2025
-
MOL.TS.165.A: Carrier Screening Panels, Including Targeted, Pan-Ethnic, Universal, and ExpandedEffective 02/01/2025 - 06/30/2025
-
MOL.TS.168.A: Familial Adenomatous Polyposis Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.169.A: Familial Hypercholesterolemia Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.170.A: Familial Malignant Melanoma Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.172.A: FMR1-Related Disorders (Fragile X) Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.182.A: Hereditary Cancer Syndrome Multigene PanelsEffective 02/01/2025 - 06/30/2025
-
MOL.TS.183.A: HFE Hemochromatosis Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.188.A: Huntington Disease Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.193.A: Li-Fraumeni Syndrome Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.194.A: Liquid Biopsy TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.197.A: Lynch Syndrome Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.199.A: Lynch Syndrome Tumor Screening - Second-TierEffective 02/01/2025 - 06/30/2025
-
MOL.TS.200.A: Mammaprint 70-Gene Breast Cancer Recurrence AssayEffective 02/01/2025 - 06/30/2025
-
MOL.TS.202.A: Marfan Syndrome Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.206.A: MUTYH Associated Polyposis Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.209.A: Non-Invasive Prenatal ScreeningEffective 02/01/2025 - 06/30/2025
-
MOL.TS.211.A: Oncotype DX for Breast Cancer PrognosisEffective 02/01/2025 - 06/30/2025
-
MOL.TS.213.A: Oncotype DX for Colorectal Cancer Recurrence RiskEffective 02/01/2025 - 06/30/2025
-
MOL.TS.215.A: PCA3 Testing for Prostate CancerEffective 02/01/2025 - 06/30/2025
-
MOL.TS.216.A: Peutz-Jeghers Syndrome Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.217.A: Prader-Willi Syndrome Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.220.A: Prenatal Maternal Serum ScreeningEffective 02/01/2025 - 06/30/2025
-
MOL.TS.222.A: Prosigna Breast Cancer Prognostic Gene Signature AssayEffective 02/01/2025 - 06/30/2025
-
MOL.TS.223.A: PTEN Hamartoma Tumor Syndromes Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.224.A: Rett Syndrome Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.225.A: Spinal Muscular Atrophy Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.227.A: Thoracic Aortic Aneurysms and Dissections (TAAD) Panel Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.228.A: Tissue of Origin Testing for Cancer of Unknown PrimaryEffective 02/01/2025 - 06/30/2025
-
MOL.TS.230.A: Somatic Mutation TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.232.A: VeriStrat Testing for NSCLC TKI ResponseEffective 02/01/2025 - 06/30/2025
-
MOL.TS.233.A: Von Hippel-Lindau Disease Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.234.A: EndoPredict for Breast Cancer PrognosisEffective 02/01/2025 - 06/30/2025
-
MOL.TS.235.A: Exome SequencingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.236.A: CxbladderEffective 02/01/2025 - 06/30/2025
-
MOL.TS.238.A: BRCA AnalysisEffective 02/01/2025 - 06/30/2025
-
MOL.TS.240.A: BCR-ABL Negative Myeloproliferative Neoplasm TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.248.A: Breast Cancer Index for Breast Cancer PrognosisEffective 02/01/2025 - 06/30/2025
-
MOL.TS.250.A: NETestEffective 02/01/2025 - 06/30/2025
-
MOL.TS.251.A: PALB2 Genetic Testing for Cancer RiskEffective 02/01/2025 - 06/30/2025
-
MOL.TS.254.A: DecisionDX Uveal MelanomaEffective 02/01/2025 - 06/30/2025
-
MOL.TS.255.A: Oncotype DX Breast DCISEffective 02/01/2025 - 06/30/2025
-
MOL.TS.257.A: Epilepsy Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.258.A: Maturity-Onset Diabetes of the Young (MODY) Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.259.A: ThyGeNEXT and ThyraMIR miRNA Gene Expression ClassifierEffective 02/01/2025 - 06/30/2025
-
MOL.TS.260.A: OVA1Effective 02/01/2025 - 06/30/2025
-
MOL.TS.264.A: Select mdxEffective 02/01/2025 - 06/30/2025
-
MOL.TS.266.A: Mitochondrial Disorders Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.267.A: Ehlers-Danlos Syndrome Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.268.A: Hereditary Connective Tissue Disorder Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.269.A: Autism, Intellectual Disability, and Developmental Delay Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.270.A: ThyroseqEffective 02/01/2025 - 06/30/2025
-
MOL.TS.271.A: PancraGENEffective 02/01/2025 - 06/30/2025
-
MOL.TS.273.A: Nonsyndromic Hearing Loss and Deafness Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.276.A: Polymerase Gamma (POLG) Related Disorders Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.282.A: DermTech Pigmented Lesion AssayEffective 02/01/2025 - 06/30/2025
-
MOL.TS.285.A: Multiple Endocrine Neoplasia Type 1 Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.286.A: Multiple Endocrine Neoplasia Type 2 Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.287.A: Hereditary Pancreatitis Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.288.A: Limb-Girdle Muscular Dystrophy Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.290.A: Facioscapulohumeral Muscular Dystrophy Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.294.A: Decipher Prostate Cancer ClassifierEffective 02/01/2025 - 06/30/2025
-
MOL.TS.295.A: Genomic Prostate ScoreEffective 02/01/2025 - 06/30/2025
-
MOL.TS.297.A: ProlarisEffective 02/01/2025 - 06/30/2025
-
MOL.TS.301.A: Neurofibromatosis Type 1 Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.302.A: Legius Syndrome Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.306.A: Genome SequencingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.307.A: AlloSure for Kidney Transplant RejectionEffective 02/01/2025 - 06/30/2025
-
MOL.TS.308.A: Hemoglobinopathies Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.309.A: Friedreich Ataxia Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.310.A: Hereditary Ataxia Multigene Panel TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.311.A: Spinocerebellar Ataxia Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.312.A: Myotonic Dystrophy Type 1 Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.324.A: CHARGE Syndrome and CHD7 Disorder Genetic Testing (previously CHARGE Syndrome Genetic Testing)Effective 02/01/2025 - 06/30/2025
-
MOL.TS.344.A: Chromosomal Microarray for Solid TumorsEffective 02/01/2025 - 06/30/2025
-
MOL.TS.356.A: Microsatellite Instability and Immunohistochemistry Testing in CancerEffective 02/01/2025 - 06/30/2025
-
MOL.TS.359.A: Inflammatory Bowel Disease Biomarker TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.360.A: Inherited Bone Marrow Failure Syndrome (IBMFS) TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.361.A: Human Platelet and Red Blood Cell Antigen GenotypingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.370.A: Inherited Thrombophilia Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.371.A: Noonan Spectrum Disorder Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.396.A: Multi-Cancer Early Detection ScreeningEffective 02/01/2025 - 06/30/2025
-
MOL.TS.401.A: Liver Fibrosis Assessment BiomarkersEffective 02/01/2025 - 06/30/2025
-
MOL.TS.410.A: Cardiomyopathy and Arrhythmia Genetic TestingEffective 02/01/2025 - 06/30/2025
-
MOL.TS.413.A: ColoSense Screening for Colorectal CancerEffective 02/01/2025 - 06/30/2025